Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neurocrine Biosciences (NBIX) Return on Sales (2016 - 2025)

Historic Return on Sales for Neurocrine Biosciences (NBIX) over the last 15 years, with Q4 2025 value amounting to 0.19%.

  • Neurocrine Biosciences' Return on Sales rose 300.0% to 0.19% in Q4 2025 from the same period last year, while for Dec 2025 it was 0.17%, marking a year-over-year increase of 200.0%. This contributed to the annual value of 0.17% for FY2025, which is 200.0% up from last year.
  • Neurocrine Biosciences' Return on Sales amounted to 0.19% in Q4 2025, which was up 300.0% from 0.26% recorded in Q3 2025.
  • In the past 5 years, Neurocrine Biosciences' Return on Sales registered a high of 0.29% during Q4 2023, and its lowest value of 0.18% during Q1 2023.
  • For the 4-year period, Neurocrine Biosciences' Return on Sales averaged around 0.14%, with its median value being 0.16% (2025).
  • The largest annual percentage gain for Neurocrine Biosciences' Return on Sales in the last 5 years was 3000bps (2021), contrasted with its biggest fall of -1200bps (2021).
  • Over the past 4 years, Neurocrine Biosciences' Return on Sales (Quarter) stood at 0.08% in 2021, then soared by 277bps to 0.29% in 2023, then tumbled by -43bps to 0.16% in 2024, then rose by 16bps to 0.19% in 2025.
  • Its Return on Sales was 0.19% in Q4 2025, compared to 0.26% in Q3 2025 and 0.16% in Q2 2025.